{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T22:27:46Z","timestamp":1787783266827,"version":"build-2784847793"},"reference-count":34,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Interleukin-17 inhibitors are effective in psoriasis; however, they are associated with an increased risk of infections, particularly oral candidiasis, and new-onset\/flares of inflammatory bowel disease. This study aimed to identify predictive markers for these adverse events and to describe the functional immune response in patients treated with interleukin-17 inhibitors using a whole-blood stimulation system (TruCulture\u00ae). Patients with psoriasis initiating an interleukin-17 inhibitor (n\u2009=\u200936) or adalimumab (n\u2009=\u200924) were enrolled. Patients attended visits at baseline, week 12, and week 52, during which skin and mucosal swabs, and faecal and blood samples were collected. Baseline oral Candida albicans colonization with no clinical symptoms was associated with an increased risk of oral candidiasis during the first year of interleukin-17 inhibitor therapy, with no cases of oral candidiasis observed in the adalimumab group. Gut inflammation, measured by faecal calprotectin, remained stable in both the adalimumab and interleukin-17 inhibitor group. Colonization with Staphylococcus aureus did not change during treatment. It was found that interleukin-17 inhibitors induced an anti-inflammatory state and potentially more active toll-like receptor 3-mediated antiviral responses compared with adalimumab. In conclusion, screening for oral Candida albicans colonization prior to initiation of interleukin-17 inhibitor therapy may be a useful strategy for risk stratification and early intervention.<\/jats:p>","DOI":"10.2340\/actadv.v105.43685","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T13:07:42Z","timestamp":1755522462000},"page":"adv43685","source":"Crossref","is-referenced-by-count":5,"title":["Adverse Events and Immune Response in Psoriasis Patients Receiving Interleukin-17 Inhibitors"],"prefix":"10.2340","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2255-398X","authenticated-orcid":false,"given":"Christopher Willy","family":"Schwarz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2414-3076","authenticated-orcid":false,"given":"Charlotte","family":"N\u00e4slund-Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5506-1319","authenticated-orcid":false,"given":"Claus","family":"Zachariae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3230-7966","authenticated-orcid":false,"given":"Jakob Benedict","family":"Seidelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6391-7455","authenticated-orcid":false,"given":"Susanne Dam","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5288-3851","authenticated-orcid":false,"given":"Sisse Rye","family":"Ostrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4651-2904","authenticated-orcid":false,"given":"Karen Marie Thyssen","family":"Astvad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger","family":"Brock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1816-4508","authenticated-orcid":false,"given":"Lars","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-9377","authenticated-orcid":false,"given":"Mads Kirchheiner","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2950-3280","authenticated-orcid":false,"given":"Nikolai","family":"Loft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9680","authenticated-orcid":false,"given":"Lone","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"121582","doi-asserted-by":"crossref","unstructured":"Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2023; 7: 6689.","DOI":"10.1002\/14651858.CD011535.pub6"},{"key":"121583","doi-asserted-by":"crossref","unstructured":"Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med 2021; 385: 142\u2013152.","DOI":"10.1056\/NEJMoa2102383"},{"key":"121584","doi-asserted-by":"crossref","unstructured":"Cho JS, Pietras EM, Garcia NC, Ramos RI, Farzam DM, Monroe HR, et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest 2010; 120: 1762\u20131773.","DOI":"10.1172\/JCI40891"},{"key":"121585","doi-asserted-by":"crossref","unstructured":"Mills KHG. IL-17 and IL-17-producing cells in protection versus pathology. Nat Rev Immunol 2023; 23: 38\u201354.","DOI":"10.1038\/s41577-022-00746-9"},{"key":"121586","doi-asserted-by":"crossref","unstructured":"Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity*. Science 2011; 332: 65\u201368.","DOI":"10.1126\/science.1200439"},{"key":"121587","doi-asserted-by":"crossref","unstructured":"Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol 2017; 177: 47\u201362.","DOI":"10.1111\/bjd.15015"},{"key":"121588","doi-asserted-by":"crossref","unstructured":"D\u2019Enfert C, Kaune AK, Alaban LR, Chakraborty S, Cole N, Delavy M, et al. The impact of the fungus-host-microbiota interplay upon Candida albicans infections: current knowledge and new perspectives. FEMS Microbiol Rev 2021; 45: 14.","DOI":"10.1093\/femsre\/fuaa060"},{"key":"121589","doi-asserted-by":"crossref","unstructured":"Sparber F, Leibundgut-Landmann S. Interleukin-17 in antifungal immunity. Pathogens 2019; 8: 54.","DOI":"10.3390\/pathogens8020054"},{"key":"121590","doi-asserted-by":"crossref","unstructured":"Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet 2022; 399: 2031\u20132046.","DOI":"10.1016\/S0140-6736(22)00466-4"},{"key":"121591","doi-asserted-by":"crossref","unstructured":"Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PDR, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012; 61: 1693\u20131700.","DOI":"10.1136\/gutjnl-2011-301668"},{"key":"121592","doi-asserted-by":"crossref","unstructured":"Targan SR, Feagan B, Vermeire S, Panaccione R, Melmed GY, Landers C, et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn\u2019s disease. Am J Gastroenterol 2016; 111: 1599\u20131607.","DOI":"10.1038\/ajg.2016.298"},{"key":"121593","doi-asserted-by":"crossref","unstructured":"Loft ND, Vaengebjerg S, Halling AS, Skov L, Egeberg A. Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Acad Dermatol Venereol 2020; 34: 1151\u20131160.","DOI":"10.1111\/jdv.16073"},{"key":"121594","doi-asserted-by":"crossref","unstructured":"Whibley N, Gaffen SL. Gut-busters: IL-17 ain\u2019t afraid of no IL-23. Immunity 2015; 43: 620.","DOI":"10.1016\/j.immuni.2015.10.001"},{"key":"121595","doi-asserted-by":"crossref","unstructured":"Bruno M, Davidson L, Koenen HJPM, van den Reek JMPA, van Cranenbroek B, de Jong EMGJ, et al. Immunological effects of anti\u2012IL-17\/12\/23 therapy in patients with psoriasis complicated by candida infections. J Invest Dermatol 2022; 142: 2929\u20132939.e8.","DOI":"10.1016\/j.jid.2022.05.1083"},{"key":"121596","doi-asserted-by":"crossref","unstructured":"Smolen JS, Mease P, Tahir H, Schulze-Koops H, De La Torre I, Li L, et al. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biological disease-modifying antirheumatic drug: final results by week 52. Ann Rheum Dis 2020; 79: 1310\u20131319.","DOI":"10.1136\/annrheumdis-2020-217372"},{"key":"121597","doi-asserted-by":"crossref","unstructured":"Todberg T, Loft N, M\u00f8ller DL, Ostrowski SR, Nielsen SD, Skov L. Impact of methotrexate and adalimumab on immune function of patients with psoriasis. Dermatol Ther 2022; 35: e15284.","DOI":"10.1111\/dth.15284"},{"key":"121598","doi-asserted-by":"crossref","unstructured":"Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117: 244\u2013279.","DOI":"10.1016\/j.pharmthera.2007.10.001"},{"key":"121599","doi-asserted-by":"crossref","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453\u20131457.","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"121600","doi-asserted-by":"crossref","unstructured":"\u00d8stg\u00e5rd RD, Deleuran BW, Dam MY, Hansen IT, Jurik AG, Glerup H. Faecal calprotectin detects subclinical bowel inflammation and may predict treatment response in spondyloarthritis. Scand J Rheumatol 2018; 47: 48\u201355.","DOI":"10.1080\/03009742.2017.1299216"},{"key":"121601","unstructured":"R Core Team (2022). R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. https:\/\/www.R-project.org\/"},{"key":"121602","doi-asserted-by":"crossref","unstructured":"Elsner K, Holstein J, Hilke FJ, Blumenstock G, Walker B, Schmidt S, et al. Prevalence of Candida species in psoriasis. Mycoses 2022; 65: 247\u2013254.","DOI":"10.1111\/myc.13399"},{"key":"121603","doi-asserted-by":"crossref","unstructured":"Picciani BLS, Michalski-Santos B, Carneiro S, Sampaio AL, Avelleira JCR, Azulay DR, et al. Oral candidiasis in patients with psoriasis: correlation of oral examination and cytopathological evaluation with psoriasis disease severity and treatment. J Am Acad Dermatol 2013; 68: 986\u2013991.","DOI":"10.1016\/j.jaad.2012.11.033"},{"key":"121604","doi-asserted-by":"crossref","unstructured":"Gordon KB, Langley RG, Warren RB, Okubo Y, Stein Gold L, Merola JF, et al. Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from phase 2 and phase 3 randomized clinical trials. JAMA Dermatol 2022; 158: 735\u2013744.","DOI":"10.1001\/jamadermatol.2022.1185"},{"key":"121605","doi-asserted-by":"crossref","unstructured":"Lemberg C, de San Vicente KM, Fr\u00f3is-Martins R, Altmeier S, Tran VDT, Mertens S, et al. Candida albicans commensalism in the oral mucosa is favoured by limited virulence and metabolic adaptation. PLoS Pathog 2022; 18: e1010012.","DOI":"10.1371\/journal.ppat.1010012"},{"key":"121606","doi-asserted-by":"crossref","unstructured":"Brizzi D, Rocco EV, Veronica E, Rocco A, Babino G, Buononato D, et al. evaluation of the role of faecal calprotectin in the management of psoriatic patients under treatment with biologic drugs. Biomedicines 2022; 10: 2968.","DOI":"10.3390\/biomedicines10112968"},{"key":"121607","doi-asserted-by":"crossref","unstructured":"Fu Y, Lee CH, Chi CC. Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol 2018; 154: 1417\u20131423.","DOI":"10.1001\/jamadermatol.2018.3631"},{"key":"121608","doi-asserted-by":"crossref","unstructured":"Burisch J, Eigner W, Schreiber S, Aletaha D, Weninger W, Trauner M, et al. Risk for development of inflammatory bowel disease under inhibition of interleukin 17: a systematic review and meta-analysis. PLoS One 2020; 15: e0233781.","DOI":"10.1371\/journal.pone.0233781"},{"key":"121609","doi-asserted-by":"crossref","unstructured":"Duffy D, Rouilly V, Libri V, Hasan M, Beitz B, David M, et al. Functional analysis via standardized whole-blood stimulation systems defines the boundaries of a healthy immune response to complex stimuli. Immunity 2014; 40: 436\u2013450.","DOI":"10.1016\/j.immuni.2014.03.002"},{"key":"121610","doi-asserted-by":"crossref","unstructured":"Blauvelt A. IL-6 differs from TNF-\u03b1: unpredicted clinical effects caused by IL-6 blockade in psoriasis. J Invest Dermatol 2017; 137: 541\u2013542.","DOI":"10.1016\/j.jid.2016.11.022"},{"key":"121611","unstructured":"Gr\u00e4n F, Kerstan A, Serfling E, Goebeler M, Muhammad K. Current developments in the immunology of psoriasis. Yale J Biol Med 2020; 93: 97."},{"key":"121612","doi-asserted-by":"crossref","unstructured":"Perales-Linares R, Navas-Martin S. Toll-like receptor 3 in viral pathogenesis: friend or foe? Immunology 2013; 140: 153\u2013167.","DOI":"10.1111\/imm.12143"},{"key":"121613","doi-asserted-by":"crossref","unstructured":"Kridin K, Zirpel H, Mruwat N, Ludwig RJ, Thaci D. Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors: a population-based study. J Eur Acad Dermatol Venereol 2023; 37: 2319\u20132326.","DOI":"10.1111\/jdv.19328"},{"key":"121614","doi-asserted-by":"crossref","unstructured":"Glintborg B, Di Giuseppe D, Wallman JK, Provan SA, Nordstr\u00f6m D, Hokkanen AM, et al. Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries. Rheumatology 2023; 62: 647\u2013658.","DOI":"10.1093\/rheumatology\/keac358"},{"key":"121615","doi-asserted-by":"crossref","unstructured":"Rezahosseini O, Liljendahl MS, Loft N, M\u00f8ller DL, Harboe ZB, Rasmussen MK, et al. Incidence, risk factors, and consequences of human alphaherpesvirus infections in patients with psoriasis who initiate methotrexate or biologic agents. J Infect Dis 2022; 226: 1510\u20131518.","DOI":"10.1093\/infdis\/jiac367"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/43685\/51096","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/43685\/51096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T13:07:47Z","timestamp":1755522467000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/43685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":34,"URL":"https:\/\/doi.org\/10.2340\/actadv.v105.43685","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,18]]}}}